Japan Tissue Engineering Co., Ltd. engages in the regenerative medicine business in Japan. The company operates through Regenerative Medicine Product, Regenerative Medicine Contract, and Lab Site Project segments. It offers autologous cultured epidermis, cartilage, corneal epithelium, and oral mucosal epithelium to medical institutions for the purpose of medical treatment. The company also provides tissue-engineered medical products. In addition, it offers EPI-MODEL, a reconstructed human epidermis model. Further, the company offers regenerative medicine contract development and manufacturing services. The company was founded in 1999 and is headquartered in Gamagori, Japan. Japan Tissue Engineering Co., Ltd. operates as a subsidiary of Teijin Limited.
Frequently asked questions
What sector does Japan Tissue Engineering Co Ltd (7774) operate in?
Japan Tissue Engineering Co Ltd belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Japan Tissue Engineering Co Ltd (7774) current stock price?
As of the latest data, Japan Tissue Engineering Co Ltd stock price is ¥790, with a previous close of ¥817. Japan Tissue Engineering Co Ltd lost -¥27 in the last trading session, representing a -3.3% loss.
What is Japan Tissue Engineering Co Ltd (7774) current market capitalization?
Japan Tissue Engineering Co Ltd market cap is approximately 32.08 billion.
What is Japan Tissue Engineering Co Ltd (7774) Earnings Per Share (EPS)?
The trailing EPS is -¥18, and the forward EPS is ¥28.
What is Japan Tissue Engineering Co Ltd (7774) EBITDA?
Japan Tissue Engineering Co Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 92.77 million.
Does Japan Tissue Engineering Co Ltd (7774) pay dividends?
No. Japan Tissue Engineering Co Ltd does not pay a dividend.
What is Japan Tissue Engineering Co Ltd (7774) beta (volatility) score?
Japan Tissue Engineering Co Ltd has a beta of 0.655, indicating lower volatility than the overall market.
